Business Wire

MA-DYNATRACE

Share
Dynatrace Positioned Highest for Ability to Execute and Furthest for Completeness in Vision in 2019 Gartner Magic Quadrant for APM

Software intelligence company Dynatrace LLC , today announced that it has been positioned highest for ‘ability to execute’ and furthest for ‘completeness of vision’ in the 2019 Gartner Magic Quadrant for Application Performance Monitoring (APM).*

“We are proud to see our position this year and extend our gratitude to our customers who constantly challenge and inspire us to keep pushing the boundaries of innovation,” said John Van Siclen, CEO of Dynatrace.

“Several years ago, we anticipated that digital transformation would be cloud-first, and that the then emerging enterprise cloud would create a major disruption throughout the application and infrastructure landscape. We took a radical approach, to rebuild from the ground-up a new platform intended to fit the new requirements of dynamic, webscale cloud monitoring. With our unique AI driven approach and advanced automation, our customers enjoy answers and insights rather than clicking through data, pouring through logs or guessing at root cause. We believe and are gratified that the market success of Dynatrace’s highly differentiated approach is being recognized by thought leaders such as Gartner.”

Steve Tack, SVP of Product Management at Dynatrace, went on to highlight the company’s secret sauce: “The AI engine, Davis, sits at the center of our solution and differentiates us from anything else. Davis can causate, quantify business impact, and drive to the precise root cause of issues, versus simple guesses based on correlation. On top of this, we opened the AI engine up to ingest data and events from third-party solutions, which enables greater automation and paves the way to autonomous cloud operations.”

We feel that Dynatrace’s solid relationship with its customers is reflected in the Gartner Peer Insights , which are customer reviews collected and verified by the analyst firm throughout the year:

  • “Dynatrace provides beyond application performance monitoring, giving you a full-stack visibility and software intelligence platform, which helps a lot of customers in identifying the issues and giving the accurate data happening [in a] customer’s environment.” – Senior IT Management Engineer in the Services industry
  • “Working with Dynatrace has been one of the best vendor experiences we have encountered in a long time. The ability to see dependencies, relationships, processes, OS metrics, and much more…just from a simple OneAgent install…is truly generation 3 monitoring. They are truly leading the way and in the right direction.” – Senior Middleware Administrator in the Manufacturing industry
  • “The best thing about the product is its ease of configuration for a cloud-hosted environment running microservices. It requires a one-off step to be repeated via automation and then the customer doesn’t need to touch the agent ever again and we still gain any new features, thanks to the auto-upgrade capabilities of the agent and the continuous deliveries that Dynatrace pushes to their live system regularly.” – Head of Technology in the Financial Services industry

Ongoing innovation and a desire to deliver more value to customers, Dynatrace continues to push beyond APM, as evidenced by a series of recent technical announcements:

*Gartner, Magic Quadrant for Application Performance Monitoring, Charley Rich, Federico De Silva, Sanjit Ganguli, 14 March 2019. Previous to 2015, Dynatrace is listed as Compuware. Dynatrace was spun off from Compuware following the privatization of Compuware in December 2014.

Gartner disclaimers

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, express or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner Peer Insights reviews constitute the subjective opinions of individual end users based on their own experiences, and do not represent the views of Gartner or its affiliates.

About Dynatrace

Dynatrace provides software intelligence to simplify enterprise cloud complexity and accelerate digital transformation. With AI and complete automation, our all-in-one platform provides answers, not just data, about the performance of applications, the underlying infrastructure and the experience of all users. That’s why many of the world’s largest enterprises trust Dynatrace to modernize and automate enterprise cloud operations, release better software faster, and deliver unrivalled digital experiences.

Curious to see how you can simply your enterprise cloud? Let us show you. Visit our trial page  for a free 15-day Dynatrace trial.

To learn more about how Dynatrace can help your business, visit https://www.dynatrace.com , visit our blog and follow us on Twitter @dynatrace .

Contact:

Hailey Melamut March Communications dynatrace@marchcomms.com +1 617.960.9856

Tristan Webb Spark Communications dynatrace@sparkcomms.co.uk +44 207.436.0420

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release

Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release

IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye